Shield Therapeutics (STX) Price & Analysis

Compare

39 Followers

STX Stock Chart & Stats

11.75p

-0.05p(-1.87%)

At close: Jan 08 4:00 PM EST

11.75p

-0.05p(-1.87%)

Day’s Range― - ―

52-Week Range2.10p - 12.50p

Previous CloseN/A

Volume699.61K

Average Volume (3M)3.16M

Market Cap

£118.92M

Enterprise Value44.14M

Total Cash (Recent Filing)£10.81M

Total Debt (Recent Filing)£27.05M

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,061,802,900

10 Day Avg. Volume1,665,963

30 Day Avg. Volume3,163,002

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-23.24

Price to Sales (P/S)0.97

P/FCF Ratio-3.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£12.50

Price Target Upside6.38% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash Flow$6.5m of cash plus successful $10m raise with AOP Health does provide some much-needed breathing room for Shield in 2025.

Prescription CoverageThe percentage of non-covered prescriptions dropped from 37% to 22%, contributing to the revenue growth.

Revenue GrowthThe significant increase in NSP in 4Q24 to $237 supported Shield delivering $32.2m in revenues for 2024, slightly ahead of expectations.

Bears Say

Cash Flow TimingThe timing at which Shield becomes cash flow positive may be delayed beyond 2025, with negative script growth being a concern.

Script GrowthNegative script growth in Q4 and a potentially soft 1Q25 driven by usual insurance renewals and unwind of year-end stocking is a concern.

Shield Therapeutics News

Shield Therapeutics Announces Block Listing Application to London Stock Exchange

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics has applied for a block listing of...

1d ago

Shield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR®

Shield Therapeutics ( ($GB:STX) ) has issued an announcement. Shield Therapeutics has been awarded Gold at the 2025...

8d ago

Shield Therapeutics Strengthens Financial Position with Amended Debt Financing

The latest update is out from Shield Therapeutics ( ($GB:STX) ). Shield Therapeutics has amended its senior secured...

16d ago

Shield Therapeutics Advances ACCRUFeR® Clinical Trials in Japan for PAH

Shield Therapeutics ( ($GB:STX) ) has provided an announcement. Shield Therapeutics announced the initiation of a Phase II...

1M ago

Shield Therapeutics to Present Pediatric PK Results at ASH Conference

Shield Therapeutics ( ($GB:STX) ) has provided an announcement. Shield Therapeutics announced the presentation of pediatric pharmacokinetic results...

1M ago

Shield Therapeutics’ ACCRUFeR® Gains Approval in South Korea

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics has announced that its product, ACCRUFeR®, has...

1M ago

Shield Therapeutics Achieves Record Quarterly Performance with ACCRUFeR®

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics reported its strongest quarterly performance to date,...

2M ago

Shield Therapeutics Grants Share Options to CEO Amidst Strategic Growth

Shield Therapeutics ( ($GB:STX) ) has provided an update. Shield Therapeutics announced the grant of share options to...

2M ago

Shield Therapeutics Announces Share Capital and Market Position of ACCRUFeR®

Shield Therapeutics ( ($GB:STX) ) just unveiled an announcement. Shield Therapeutics has announced that its total issued share...

3M ago

Shield Therapeutics Reports Positive Pediatric Trial Results for Ferric Maltol

Shield Therapeutics ( ($GB:STX) ) has shared an announcement. Shield Therapeutics announced positive results from its Phase 3...

3M ago

STX FAQ

What was Shield Therapeutics PLC’s price range in the past 12 months?

Shield Therapeutics PLC lowest share price was 2.10p and its highest was 12.50p in the past 12 months.

What is Shield Therapeutics PLC’s market cap?

Shield Therapeutics PLC’s market cap is £118.92M.

When is Shield Therapeutics PLC’s upcoming earnings report date?

Shield Therapeutics PLC’s upcoming earnings report date is Apr 23, 2026 which is in 125 days.

How were Shield Therapeutics PLC’s earnings last quarter?

Shield Therapeutics PLC released its earnings results on Aug 21, 2025. The company reported -0.007p earnings per share for the quarter, missing the consensus estimate of N/A by -0.007p.

Is Shield Therapeutics PLC overvalued?

According to Wall Street analysts Shield Therapeutics PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shield Therapeutics PLC pay dividends?

Shield Therapeutics PLC does not currently pay dividends.

What is Shield Therapeutics PLC’s EPS estimate?

Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shield Therapeutics PLC have?

Shield Therapeutics PLC has 1,061,802,900 shares outstanding.

What happened to Shield Therapeutics PLC’s price movement after its last earnings report?

Shield Therapeutics PLC reported an EPS of -0.007p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.716%.

Which hedge fund is a major shareholder of Shield Therapeutics PLC?

Currently, no hedge funds are holding shares in GB:STX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shield Therapeutics Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
£12.50 (6.38% Upside)

Technicals

Fundamentals

Return on Equity

-396.71%

Trailing 12-Months

Asset Growth

22.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shield Therapeutics PLC

Shield Therapeutics (STX) is a specialty pharmaceutical company focused on developing and commercializing innovative iron therapies for patients with iron deficiency and related conditions. The company operates primarily in the healthcare sector, offering its flagship product, Accrufer (ferric maltol), which is designed to treat iron deficiency anemia in adults. Shield Therapeutics aims to provide effective and safe treatment options that enhance patient quality of life while addressing significant unmet medical needs in the market.

Shield Therapeutics (STX) Earnings & Revenues

Historic Earnings Reports

STX Stock 12 Month Forecast

Average Price Target

12.50p

▲(6.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"0p","4":"4p","8":"8p","12":"12p","16":"16p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">15.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">12.50p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">10.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.7,10.107692307692307,10.515384615384615,10.923076923076923,11.33076923076923,11.738461538461538,12.146153846153846,12.553846153846154,12.961538461538462,13.369230769230768,13.776923076923076,14.184615384615384,14.592307692307692,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.7,9.915384615384614,10.13076923076923,10.346153846153845,10.561538461538461,10.776923076923076,10.992307692307692,11.207692307692307,11.423076923076923,11.638461538461538,11.853846153846154,12.069230769230769,12.284615384615385,{"y":12.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.7,9.723076923076922,9.746153846153845,9.769230769230768,9.792307692307691,9.815384615384614,9.838461538461537,9.861538461538462,9.884615384615385,9.907692307692308,9.930769230769231,9.953846153846154,9.976923076923077,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.15,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >